MYF5 and neoplasm: Conversely, the second niche, identified primarily in patients who did not respond to mono-immunotherapy, is distinguished by the proliferation of STMN1+ cECs and a significant accumulation of MYF5+ MSCs at the invasive frontiers of the tumor.